Acquired Company

Bristol Myers Squibb completed its acquisition of RayzeBio on February 26, 2024, and RayzeBio became a wholly owned subsidiary of Bristol Myers Squibb.

RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company is headquartered in San Diego, California. Show more

5505 MOREHOUSE DRIVE, SAN DIEGO, CA, UNITED STATES, 92121, USA

https://rayzebio.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

3.718B

52 Wk Range

$0.00 - $0.00

Previous Close

$62.49

Open

$62.49

Volume

N/A

Day Range

$62.49 - $62.49

Enterprise Value

0.00

Cash

252M

Avg Qtr Burn

-17.26M

Insider Ownership

9.69%

Institutional Own.

89.71%

Qtr Updated

09/30/23

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
RYZ101 Details Small cell lung cancer, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RYZ101 Details Gastroenteropancreatic neuroendocrine tumors, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.